
Wonderfeel NMN Supplements Under Review: Potent Activated NAD+ Boosting Youngr & Capsuls Formulas
New York, May 03, 2025 (GLOBE NEWSWIRE) —
In This Article, You'll Discover: Why NAD+ is critical for cellular energy, DNA repair, and healthy aging
How Wonderfeel's NMN supplements—Youngr™ and Capsuls™—support mitochondrial health and longevity
The key differences between NMN and NR, and why NMN is the preferred NAD+ precursor
A full breakdown of the advanced multi-ingredient formula found in Wonderfeel Youngr™
Why Wonderfeel Capsuls™ is ideal for those seeking a pure, high-dose NMN option
How declining NAD+ levels impact energy, focus, mood, metabolism, and skin health
What sets Wonderfeel apart from other NMN brands in terms of science, purity, and transparency
Real user testimonials, purchasing details, subscription options, and refund policies
Frequently asked questions addressing NAD+ optimization, bioavailability, and results expectations
Where to buy authentic Wonderfeel NMN supplements and how to get exclusive savings
TL;DR Summary
This in-depth review explores Wonderfeel NMN Supplements, spotlighting two flagship products—Youngr™ and Capsuls™—engineered to boost NAD+ levels and support cellular energy, longevity, and mental clarity. The article explains how NAD+ decline affects aging, why Nicotinamide Mononucleotide (NMN) is a superior precursor, and how Wonderfeel's clean-label, science-driven formulas deliver advanced support for mitochondrial health, sirtuin activation, and metabolic optimization. With expert-backed ingredient synergy, clinical-grade quality, and flexible pricing options, Wonderfeel emerges as a leading name in NAD+ boosting supplements. Ideal for adults 35+, biohackers, and wellness-focused individuals seeking a trusted solution to optimize healthspan.
Always consult a healthcare provider before starting supplementation. Prices are subject to change—check the official website at https://getwonderfeel.com for the most accurate and updated information.
The Quest for Cellular Vitality
Why More People Are Seeking Longevity Solutions
In recent years, the pursuit of vitality and longevity has become a major trend, especially among health-conscious individuals and aging populations who are not just trying to extend their lifespan but also improve the quality of their years. With more people experiencing fatigue, foggy thinking, and visible signs of aging even before their 40s, the focus has shifted to addressing the urgent root causes of these changes: cellular decline and metabolic slowdown.
One of the most talked-about terms in this space is NAD+, a vital molecule that plays a key role in cellular energy production, DNA repair, and overall mitochondrial function. When NAD+ levels drop—as they naturally do with age—individuals may begin to feel slower, less mentally sharp, and more prone to health challenges that were once rare in youth. The significance of NAD+ in these processes cannot be overstated.
This growing demand for proactive wellness has birthed an entire industry focused on biohacking, longevity supplementation, and cellular rejuvenation. People are turning to solutions that support epigenetic resets, promote autophagy, and claim to slow the biological aging process without extreme interventions.
The Link Between NAD+ and Everyday Wellness
Modern science increasingly supports the idea that enhancing NAD+ availability in the body can play a foundational role in supporting energy metabolism, brain health, and even skin resilience. NAD+ is often referred to as the 'youth molecule' by longevity researchers because of its central role in sirtuin activation, a class of proteins associated with lifespan extension and age-related repair processes.
However, NAD+ itself cannot be taken directly as a supplement due to poor bioavailability. Instead, precursors like NMN (Nicotinamide Mononucleotide) and NR (Nicotinamide Riboside) are used, as they convert efficiently to NAD+ in the body. Of the two, NMN has gained rapid popularity for its ability to be readily absorbed and quickly transformed into NAD+ in tissues that need it most.
This is where Wonderfeel enters the conversation, delivering an advanced formulation that not only provides high-dose NMN but also integrates synergistic ingredients designed to support the full spectrum of cellular function and well-being.
Enter Wonderfeel: The Science of Feeling Younger
As the supplement world becomes flooded with generic NMN products, Wonderfeel has carved out a unique position with its line of cutting-edge solutions: Youngr™ NMN Supplement and Capsuls™ Pure NMN Formula. These products are designed for those who are serious about supporting their NAD+ levels using scientifically grounded ingredients formulated for maximum bioavailability, efficacy, and purity. Choosing high-quality supplements like these can provide a sense of reassurance in your health journey.
Created by renowned biomedical researcher Dr. Andrew Salzman, Wonderfeel's offerings stand out for more than just their clean ingredient labels—they are engineered with a deep understanding of human biology and the mechanisms that govern aging and cell regeneration.
These products do not promise miracles or biological immortality. Instead, they offer a strategic, high-quality NAD+ boosting solution for those who want to feel more energetic, mentally focused, and resilient to the physical effects of aging.
Understanding NAD+ and NMN
The Power Molecule Behind Cellular Energy
NAD+ (Nicotinamide Adenine Dinucleotide) is a coenzyme found in every cell of the body. It plays a pivotal role in cellular metabolism, helping convert nutrients into usable energy. Beyond energy production, NAD+ is also essential for activating proteins called sirtuins, which regulate DNA repair, inflammation, and aging-related processes. As we age, NAD+ levels decline, which contributes to feelings of fatigue, slower recovery, brain fog, and an increased risk of age-related issues.
Declining NAD+ is a natural part of the aging process. Studies show that by middle age, NAD+ levels can drop by as much as 50%. This loss in cellular energy and repair capacity may contribute to the onset of age-related symptoms—even in people who maintain a healthy diet and active lifestyle.
The global wellness and longevity movement has brought attention to NAD+ boosting strategies, including exercise, fasting, and nutritional supplementation. Among these,NMN (Nicotinamide Mononucleotide) has become one of the most researched and effective options for naturally increasing NAD+ levels.
What Is NMN and Why Is It a Game Changer?
NMN, as a direct precursor to NAD+, offers a ray of hope. The body can convert it into NAD+ more efficiently than most other molecules, making it a top contender in the anti-aging and biohacking spaces. This is especially encouraging for those who seek mitochondrial health support, epigenetic optimization, and cognitive clarity as they age.
Unlike traditional multivitamins or herbal remedies, NMN operates at the cellular level, directly supporting the body's natural processes of energy production and repair. It is increasingly used by high performers, athletes, health-conscious individuals, and older adults looking to maintain or restore their vitality.
NMN vs. NR: Which NAD+ Precursor Is Better?
When considering NAD+ supplements, it's important to understand the unique advantages of NMN (Nicotinamide Mononucleotide) over NR (Nicotinamide Riboside). Both are NAD+ precursors, but NMN has shown some distinct benefits: Direct Conversion Pathway , a term used to describe the process by which a precursor is converted into a substance, is an important factor when considering NAD+ supplements. NMN converts to NAD+ more efficiently than NR, especially in tissues such as the liver, brain, and muscles.
, a term used to describe the process by which a precursor is converted into a substance, is an important factor when considering NAD+ supplements. NMN converts to NAD+ more efficiently than NR, especially in tissues such as the liver, brain, and muscles. Bioavailability , a term used to describe the proportion of a drug or other substance that enters the circulation when introduced into the body and so is able to have an active effect, is an important factor when considering NAD+ supplements. NMN has been shown to be highly bioavailable in oral form, especially in capsule delivery formats like those offered by Wonderfeel.
, a term used to describe the proportion of a drug or other substance that enters the circulation when introduced into the body and so is able to have an active effect, is an important factor when considering NAD+ supplements. NMN has been shown to be highly bioavailable in oral form, especially in capsule delivery formats like those offered by Wonderfeel. More Research-Backed Use in Aging: NMN is more frequently cited in current longevity research, including work conducted by leaders in the field of anti-aging.
These distinctions make NMN a preferred choice for many seeking advanced cellular rejuvenation and metabolic optimization.
How NAD+ & NMN Fit Into the Bigger Picture of Healthspan
The concept of healthspan—the number of years we live in good health—is becoming more important than simply lifespan. NAD+ and NMN are crucial to this mission, supporting not only how long we live but also how well we function at every age. Through their role in energy production, DNA integrity, and inflammation modulation, NAD+ levels affect everything from muscle recovery and mental focus to immune resilience and emotional well-being.
This is where premium formulations like Wonderfeel's Youngr™ and Capsuls™ offer a tangible advantage. They're designed not only to boost NAD+ levels, but also to support the surrounding systems that influence how we feel and perform daily.
Remember, the information presented here is for educational purposes only. Your health is unique, so it's always best to consult with your healthcare provider before starting any new supplement regimen. This ensures your safety and the best possible outcomes for your health.
Unlock the power of cellular renewal—start your journey with Wonderfeel Youngr™ or Capsuls™ today and experience the energy, clarity, and resilience your body has been craving.
Introducing Wonderfeel: A Pioneer in Longevity Science
The Vision Behind the Brand
Wonderfeel was born from a revolutionary idea: to empower people to take control of their aging process through science-backed solutions rooted in advanced longevity research. Founded by Harvard-educated physician and biomedical researcher Dr. Andrew Salzman, Wonderfeel sets itself apart by fusing cutting-edge science with real-world wellness outcomes.
Dr. Salzman holds more than 50 medical patents and brings decades of experience in clinical pharmacology and molecular biology to the brand's foundation. His approach to product formulation is guided by evidence, not marketing hype—making Wonderfeel one of the few supplement companies rooted in true medical innovation rather than fad-based trends.
In an era when the supplement industry is crowded with under-dosed, unregulated formulas, Wonderfeel's unwavering commitment to integrity, transparency, and research gives consumers a sense of reassurance and confidence. They can rest assured that they are investing in efficacy, safety, and biological relevance.
Clean Formulations with a Purpose
All Wonderfeel products, including Youngr™ and Capsuls™, are manufactured in the United States in cGMP-certified facilities. These facilities follow rigorous quality standards to ensure product purity, ingredient traceability, and dosage consistency. Every batch is third-party tested for quality, which is an essential differentiator in the modern supplement market.
Their formulas are: Vegan
Non-GMO
Free from gluten, soy, and dairy
Made without unnecessary fillers or synthetic additives
Wonderfeel's clean-label philosophy resonates strongly with today's wellness consumers who seek natural NAD+ boosters, anti-aging biohacker stacks, and minimalist longevity support. This alignment with the brand's values makes consumers feel a part of Wonderfeel's mission without compromising on quality.
Why Wonderfeel Is Gaining Momentum in the Biohacking World
The longevity movement is not just about living longer—it's about living better, with enhanced clarity, energy, and resilience. Wonderfeel's products directly support this mission, with clinical precision and lifestyle compatibility.
Its flagship formulations—Youngr™ and Capsuls™—are specifically engineered to provide targeted support for: Cellular repair and DNA integrity
Cognitive enhancement and neuroprotection
Mitochondrial performance and sustained energy
Inflammation modulation and oxidative stress balance
By focusing on the cellular root causes of aging rather than symptoms, Wonderfeel products appeal to both elite biohackers and everyday individuals alike. This approach educates and informs the audience about the deep biological level at which Wonderfeel's solutions work, optimizing their healthspan.
Trust Built on Evidence, Not Marketing
Wonderfeel doesn't rely on vague promises or pseudo-scientific language. Their website features scientific citations, expert interviews, and transparent breakdowns of each ingredient's role in human physiology. This positions them as a thought leader in the nutritional longevity space, particularly for those who value transparency over gimmicks.
Wonderfeel has also gained traction through: Mentions in leading longevity podcasts
Features in wellness publications
Testimonials from early adopters in the biohacking and performance health community
This kind of third-party credibility helps reinforce the brand's commitment to results-driven products that align with the latest anti-aging research and cellular rejuvenation insights.
Step into your peak potential—reclaim vitality, focus, and strength at the cellular level with the trusted science of Wonderfeel NMN supplements.
Deep Dive into Wonderfeel Youngr™
A Next-Level NMN-Based Formula for Healthy Aging
Among Wonderfeel's product line, Youngr™ NMN Supplement stands as a flagship innovation tailored for those who want a multi-layered longevity formula. Unlike standard NMN capsules that provide a single compound, Youngr™ is an advanced formulation with an ensemble of bioactive ingredients designed to synergistically support NAD+ production, antioxidant defense, cognitive function, and immune balance.
The formulation is built not just for raising NAD+ levels—but also to protect, sustain, and optimize the benefits of elevated NAD+ within the body.
What's Inside the Youngr™ Formula?
Each serving of Youngr™ includes: NMN (Nicotinamide Mononucleotide) – 900 mg: The central NAD+ precursor that helps replenish declining cellular energy reserves with age. NMN supports enhanced mitochondrial performance, DNA repair, and metabolic efficiency.
The central NAD+ precursor that helps replenish declining cellular energy reserves with age. NMN supports enhanced mitochondrial performance, DNA repair, and metabolic efficiency. Trans-Resveratrol – 50 mg: A polyphenol known for its role in activating sirtuins, the proteins linked to cellular protection and aging defense. Resveratrol is often stacked with NMN in biohacker protocols for maximum synergy.
A polyphenol known for its role in activating sirtuins, the proteins linked to cellular protection and aging defense. Resveratrol is often stacked with NMN in biohacker protocols for maximum synergy. Hydroxytyrosol – 10 mg: A potent antioxidant derived from olives, known to support cardiovascular health and reduce oxidative stress. This ingredient provides support for mitochondrial resilience and immune strength.
A potent antioxidant derived from olives, known to support cardiovascular health and reduce oxidative stress. This ingredient provides support for mitochondrial resilience and immune strength. Ergothioneine – 2 mg: Sometimes called the 'longevity vitamin,' this rare amino acid acts as a powerful antioxidant. It helps safeguard cellular components from damage and is believed to play a role in healthy aging.
Sometimes called the 'longevity vitamin,' this rare amino acid acts as a powerful antioxidant. It helps safeguard cellular components from damage and is believed to play a role in healthy aging. Vitamin D3 (Cholecalciferol) – 10 mcg: Supports immune health, bone integrity, and mood regulation. Vitamin D3 adds another foundational wellness layer to Youngr™, which is important since low D levels are increasingly common with age.
This multi-ingredient profile gives Youngr™ the edge over basic NMN-only formulas. It's engineered for whole-body vitality, making it ideal for users seeking a comprehensive cellular optimization stack, ensuring you're well-cared for in your wellness journey.
Bioavailability Matters: Why Delivery Format Counts
One of the most overlooked issues in NAD+ boosting supplements is ingredient stability and bioavailability. Wonderfeel addresses this with a carefully engineered capsule that maintains NMN's stability and promotes optimal absorption once ingested.
Paired with antioxidant co-factors like resveratrol and hydroxytyrosol, the formulation is designed to preserve NMN during metabolism, helping it reach the bloodstream effectively. This is critical in ensuring that the NAD+ benefits aren't lost during digestion.
Unlike powders that degrade quickly or poorly tested blends, Youngr™ has been crafted for maximum uptake and systemic delivery—an essential trait for serious anti-aging interventions.
Key Benefits for Consistent Use
While results can vary by individual, many users of Youngr™ have reported: Increased daily energy and mental clarity
Sharper focus and improved memory recall
Better stress resilience and mood stability
Enhanced skin tone and recovery from fatigue
Greater motivation to exercise and move
Disclaimer: These benefits are anecdotal and have not been evaluated by the Food and Drug Administration. Wonderfeel products are not intended to diagnose, treat, cure, or prevent any disease.
It's worth noting that many of these effects may take several weeks of consistent use, as NAD+ levels gradually build in the system.
Who Should Consider Youngr™?
This formulation is especially well-suited for: Adults aged 35+ looking to support long-term wellness
Busy professionals seeking cognitive stamina
Biohackers who want an all-in-one NAD+ and antioxidant blend
Health-conscious individuals aiming for proactive aging strategies
Athletes or fitness enthusiasts in need of cellular energy recovery
Whether you're concerned with brain fog, fatigue, or simply want to future-proof your health, Youngr™ provides an advanced, science-backed approach to youthful cellular performance.
Why wait for aging to take its toll? Choose Wonderfeel now and give your body the advanced support it needs to thrive, not just survive.
Exploring Wonderfeel Capsuls™
Experience the Reassuring simplicity and Purity of Wonderfeel Capsuls™While Wonderfeel's Youngr™ supplement delivers a multifaceted formulation, Capsuls™ is a more streamlined, high-potency option designed for those who want pure NMN support without added co-ingredients. This formula is ideal for individuals who already take complementary supplements and want to stack NMN into their routine without redundancy or interaction concerns.
Each serving of Wonderfeel Capsuls™ contains: NMN (Nicotinamide Mononucleotide) – 1000 mg
Delivered in its purest, most bioavailable form, this potent dose supports the body's NAD+ biosynthesis directly and efficiently. At 1,000 mg per serving, Capsuls™ is one of the highest-dosed NMN products on the market, providing a secure and confident choice that is still tested for purity and backed by credible sourcing.Capsuls™ focuses on one goal: maximizing NAD+ production at a therapeutic level. For many users, especially those aged 40+, this direct support plays a key role in reclaiming energy, supporting mitochondrial function, and enhancing stress response systems.
Why Go Pure? The Appeal of a Singular Focus
Capsuls™ is not trying to be a multivitamin or antioxidant blend. Its appeal lies in its clean, single-ingredient structure, which makes it an attractive choice for: Supplement minimalists
Sensitive individuals wanting to avoid additional compounds
People already using resveratrol, CoQ10, or vitamin D separately
Biohackers who prefer modular supplement stacking
In this way, Capsuls™ becomes a customizable NAD+ backbone, adaptable to various protocols. It is vegan, gluten-free, non-GMO, and free from artificial fillers—just clean, clinical NMN.
How Capsuls™ Supports the Aging Body
While both Youngr™ and Capsuls™ boost NAD+, the simplicity of Capsuls™ makes it more focusedforcertain goals. For instance: Mental Clarity: With NAD+ playing a central role in neurotransmitter production and brain energy, consistent NMN intake may support better focus and cognition as you age.
Muscle Function: Elevated NAD+ supports better ATP production, the body's cellular energy currency, which may benefit physical performance and recovery.
DNA Repair Pathways: NAD+ is required for activating enzymes that repair DNA damage, a natural process that becomes less efficient with age.
Mitochondrial Revitalization: Aging is directly linked to a decline in mitochondrial performance. Capsuls™ helps supply the metabolic fuel needed to support healthier, more active mitochondria.
Disclaimer: These statements are not intended to diagnose, treat, cure, or prevent any disease. Results may vary from person to person. Please consult your healthcare provider before beginning supplementation.
Clean Manufacturing and Quality Assurance
Capsuls™ is crafted with the same high standards Wonderfeel applies to all its formulations: Manufactured in USA-based, cGMP-certified facilities
Third-party tested for purity, safety, and identity
Shipped in dark, protective packaging to maintain potency
Wonderfeel makes all lab data available upon request, offering complete transparency and peace of mind for the discerning supplement user.
Who Should Use Wonderfeel Capsuls™?
This product is ideal for: Individuals new to NAD+ support looking to test NMN's effects
Advanced supplement users already taking synergistic compounds separately
Men and women over 40 focused on aging prevention
Minimalist health consumers who want maximum impact from a single compound
Capsuls™ is one of the few NAD+ supplements with both clinical backing and dosing strength, which is increasingly important for anyone looking to sustain performance at a cellular level.
Live with purpose, age with confidence—boost NAD+ the right way with Wonderfeel's science-backed, clean-label NMN formulations today.
Addressing Common Health Concerns
The Silent Toll of Declining NAD+ Levels
Many people today struggle with symptoms that are often dismissed as a 'normal part of aging': low energy, trouble concentrating, sluggish metabolism, joint stiffness, poor sleep, and skin changes. While these issues may appear disconnected on the surface, they can often be traced back to a common biological thread—the age-related decline of NAD+.
As NAD+ levels fall, cellular energy production weakens. NAD+ is a coenzyme found in all living cells and is involved in the transfer of energy from nutrients to the cell. Mitochondria—the energy factories of the cell—become less efficient due to the decline in NAD+. This drop in cellular vitality may contribute to both mental and physical fatigue, slower recovery times, and even susceptibility to oxidative stress and inflammation.
It's not just about feeling older—it's about feeling like your body and brain aren't performing at their best, even when you're doing everything 'right.'
Wonderfeel's Approach to Whole-Body Longevity Support
Wonderfeel products are not just another wellness trend, but a result of rigorous scientific research. They are strategically designed to address multiple dimensions of health affected by low NAD+, offering real, science-driven support for individuals navigating these age-associated challenges. This emphasis on science can make the audience feel more informed and knowledgeable about the products they are considering.
Fatigue and Low Energy Problem: Many people feel exhausted even after a full night's sleep. Mitochondrial inefficiency is a hidden cause.
Many people feel exhausted even after a full night's sleep. Mitochondrial inefficiency is a hidden cause. Solution: By boosting NAD+, NMN helps fuel mitochondrial energy output, potentially leading to increased daytime energy and reduced crash cycles.
Brain Fog and Focus Issues Problem: Cognitive slowdown, memory lapses, and poor concentration are often associated with age-related neurological changes and reduced neuronal energy.
Cognitive slowdown, memory lapses, and poor concentration are often associated with age-related neurological changes and reduced neuronal energy. Solution: Elevated NAD+ can support neurotransmitter balance and neuroprotection. Wonderfeel Youngr™ adds ingredients like resveratrol and ergothioneine for cognitive synergy.
Metabolic Slowdown and Weight Management Problem: Aging bodies tend to burn fewer calories at rest, and insulin sensitivity often declines—making weight management more difficult.
Aging bodies tend to burn fewer calories at rest, and insulin sensitivity often declines—making weight management more difficult. Solution: NAD+ plays a key role in metabolic signaling. NMN supplementation has been studied for its role in supporting metabolic function and healthy insulin response.
NAD+ plays a key role in metabolic signaling. NMN supplementation has been studied for its role in supporting metabolic function and healthy insulin response. Disclaimer: These outcomes are not guaranteed and should not replace medical guidance. Always consult a healthcare provider for metabolic concerns.
Stress, Immunity, and Mood Problem: Chronic stress, low immunity, and unstable moods are increasingly linked to cellular aging and inflammation.
Chronic stress, low immunity, and unstable moods are increasingly linked to cellular aging and inflammation. Solution: By restoring NAD+ balance and supporting cellular repair, Wonderfeel supplements may help the body become more resilient to internal and environmental stressors.
Skin Health and Visible Aging Problem: Wrinkles, dullness, and thinning skin are visual markers of deeper biological aging, often linked to oxidative damage and slower cell turnover.
Wrinkles, dullness, and thinning skin are visual markers of deeper biological aging, often linked to oxidative damage and slower cell turnover. Solution: Youngr™ contains powerful antioxidants like hydroxytyrosol and ergothioneine to combat free radicals. Combined with NAD+ elevation, this may contribute to improved skin tone and texture.
Youngr™ contains powerful antioxidants like hydroxytyrosol and ergothioneine to combat free radicals. Combined with NAD+ elevation, this may contribute to improved skin tone and texture. Disclaimer: Results will vary. This product is not intended to diagnose or treat skin conditions.
A Holistic Alternative to Traditional Anti-Aging Approaches
Unlike harsh pharmaceutical interventions or invasive cosmetic procedures, Wonderfeel offers a non-invasive, science-based method to address the root causes of aging-related symptoms. This natural approach can reassure the audience and instill confidence in the brand's products.
This resonates with a growing wave of consumers seeking natural NAD+ boosters, bioavailable longevity supplements, and trusted anti-aging alternatives that don't come with major side effects or unrealistic expectations.
Experience wellness from the inside out—start Wonderfeel now and discover why it's the go-to NMN supplement for biohackers and longevity seekers.
Scientific Backing and Clinical Insights
The Science Behind NAD+ and Aging
NAD+ has become one of the most researched molecules in longevity science. Numerous peer-reviewed studies and lab trials have highlighted its central role in energy metabolism, mitochondrial health, and age-related DNA repair. These findings have led to NAD+ precursors like NMN gaining attention among anti-aging researchers, biohackers, and clinical health professionals alike.
Research shows that supplementing with NMN can restore NAD+ levels in various tissues, including the brain, liver, and muscles. In animal studies, this has led to improved insulin sensitivity, better cognitive function, and extended healthspan. While human studies are still emerging, early data is promising—and Wonderfeel aligns its product development with this research trajectory.
Remember, while animal studies are informative, outcomes may differ in humans. It's crucial to consult your healthcare provider before making decisions based on emerging research. This responsible approach ensures you're always well-informed and making the best choices for your health.
Wonderfeel's Formulations Are Rooted in Biomedical Innovation
What sets Wonderfeel apart is its science-first approach. Dr. Andrew Salzman, the company's co-founder, is a globally recognized medical scientist with over 50 U.S. patents and decades of experience in cellular pharmacology. His leadership ensures that each formulation is backed by rational dosing protocols, ingredient synergy, and clinical relevance.
Rather than crowding products with trendy compounds, Wonderfeel focuses on a mechanistic formulation strategy—targeting the biological processes that underlie aging: Sirtuin Activation via NMN and resveratrol
Oxidative Stress Reduction through hydroxytyrosol and ergothioneine
Immune Function Support with vitamin D3
Cognitive Health Optimization from mitochondrial enhancement and NAD+ repair enzymes
These ingredients aren't just popular—they serve distinct biochemical functions that work in concert to promote system-wide balance and youthful resilience.
Comparative Insights: Wonderfeel vs. Other NMN Brands
Wonderfeel doesn't operate in a vacuum. It competes with many NMN products on the market, including those from well-known names like Tru Niagen, Elysium Basis, and Toniiq. However, where most competitors offer either low-dose NMN or single-compound formulas, Wonderfeel delivers: High-dose NMN: 900 mg (Youngr™) and 1000 mg (Capsuls™) per serving
Synergistic antioxidants: Resveratrol, hydroxytyrosol, ergothioneine
Science-led design: Founded by a medical doctor, with peer-reviewed validation guiding product development
Third-party testing: Ensures purity and potency of every batch
Manufactured in cGMP-certified U.S. facilities
This positions Wonderfeel as not just a supplement brand—but a transformative longevity solution provider for discerning users who value transparency and effectiveness, offering a hopeful path towards a healthier, more resilient future.
Clinical Observations and Real-World Data
While Wonderfeel's products have not undergone full-scale clinical trials, anecdotal reports and preliminary user feedback indicate substantial perceived benefits: Enhanced mental clarity and energy levels
Improved mood stability and resilience under stress
Faster recovery from workouts or physical fatigue
Clearer skin tone and reduced puffiness
Stabilized sleep cycles and less morning grogginess
Again, it's important to emphasize:
Disclaimer: These reported experiences are not substitutes for clinical results. Wonderfeel products are not intended to treat or cure any condition. Individual results may vary.
What's most impressive is Wonderfeel's unwavering commitment to evolving with new science. They regularly review updated studies, adjust sourcing standards, and refine formulations based on the latest discoveries in cellular longevity research, epigenetics, and nutrigenomics, ensuring you can always trust in the reliability and effectiveness of their products.
You've optimized your diet and routine—now it's time to optimize your cells. Wonderfeel's NMN supplements are the final step toward true vitality.
User Testimonials and Reviews
Real People, Real Experiences
As with any supplement, the best way to gauge its impact is often through the stories of those who use it daily. Wonderfeel has gathered feedback from a diverse and inclusive group of users—ranging from health-focused professionals and high-performance executives to wellness seekers in their 40s, 50s, and beyond. You could be one of them.
While individual results vary, many users of Youngr™ and Capsuls™ have reported noticeable improvements within the first few weeks of consistent use.
Common experiences include: Feeling more alert and mentally sharp throughout the day
Improved stamina during workouts and daily activities
Greater motivation to engage in healthy habits
Enhanced sense of well-being and emotional balance
Decreased recovery time after physical or cognitive stress
Users often describe the changes not as a sudden 'high,' but as a gradual return to the clear-headed, energetic, and resilient state they experienced in their younger years.
It's important to note that these are anecdotal reports from real users. Individual responses may vary based on age, health status, and lifestyle. Our supplement is not intended to diagnose, treat, or prevent any disease.
Highlights From Online Reviews and Community Feedback
Wonderfeel has been praised not just for its product efficacy, but for its clarity in labeling, scientific transparency, and customer-first approach. Users especially appreciate: No unnecessary fillers or additives
Sustainable energy without jitters
Third-party test results available upon request
Easy subscription management and timely delivery
Many testimonials refer to Wonderfeel as a brand they trust more than other NAD+ competitors, citing the clinical credibility of its founder and the superior quality of its formulations.
Across forums, Reddit threads, and wellness blogs, Wonderfeel is frequently mentioned among the top-tier NMN supplements—alongside brands like DoNotAge, Elysium, and Renue by Science—but with the unique benefit of full-spectrum ingredient synergy in the Youngr™ formula.
Purchasing Details and Subscription Options
Transparent Pricing with Flexible Options
Wonderfeel provides two premium NAD+ boosting products, each with theirown pricing tier:
Youngr™ (60 Capsules | 30 Servings) One-Time Purchase: $88
Monthly Subscription: $73/month
(Save 17% with auto-renewal)
Capsuls™ (60 Capsules | 30 Servings) One-Time Purchase: $58
Monthly Subscription: $52/month
(Save 10% with auto-renewal)
Bulk Discounts: 3-packs and 6-packs are available for both products, offering additional savings for long-term users.
Disclaimer on Pricing: Prices are subject to change at any time. For the most accurate and current information, please visit the official Wonderfeel website: https://getwonderfeel.com.
Shipping and Return Policy Shipping: Free standard shipping in the U.S.; international shipping available at calculated rates.
Returns: 30-day refund available for unopened products only. Customers are responsible for return shipping costs.
Contact and Customer Service
Wonderfeel is committed to providing a seamless customer experience, from product transparency to order fulfillment. You can trust us to deliver on our promises.
Ready to outsmart aging? Choose Wonderfeel's clinically designed NMN stacks and feel younger, sharper, and more energized every single day.
Conclusion: Is Wonderfeel the Best NMN Supplement for You?
Bridging the Gap Between Science and Everyday Wellness
In today's fast-paced, high-stress environment, more individuals are seeking ways to take control of their biological aging and preserve their healthspan—not just their lifespan. This is where Wonderfeel delivers immense value. With a research-backed foundation, clean ingredient sourcing, and a commitment to quality, Wonderfeel stands out as one of the most trusted names in the NAD+ boosting supplement market.
Their two flagship products—Youngr™ and Capsuls™—each offer a distinct solution for supporting cellular health, depending on your personal goals: Youngr™ delivers a multi-ingredient formula that combines 900 mg of NMN with antioxidants like resveratrol, ergothioneine, hydroxytyrosol, and vitamin D3, creating a powerful stack for individuals seeking whole-body longevity support and sirtuin activation.
Capsuls™, on the other hand, offers 1000 mg of pure NMN for those who prefer a clean, focused formulation to integrate into their biohacking protocol or existing wellness stack.
Both options are vegan, non-GMO, third-party tested, and manufactured in cGMP-certified facilities in the United States—demonstrating Wonderfeel's dedication to both safety and efficacy.
Who Benefits Most from Wonderfeel NMN?
Whether you're a high-performance professional battling mental fatigue, an older adult aiming to support graceful aging, or a wellness enthusiast seeking enhanced mitochondrial health and cognitive clarity, Wonderfeel NMN supplements offer an advanced, science-aligned path forward.
Common reasons people choose Wonderfeel include: Persistent energy dips and physical fatigue despite healthy lifestyle habits
Cognitive fog, trouble concentrating, or short-term memory issues
Seeking anti-aging support at a cellular level without harsh pharmaceuticals
Wanting to improve resilience to stress, immune balance, and skin health
Exploring bioavailable longevity supplements with proven mechanisms of action
The choice to invest in NAD+ restoration is not about avoiding aging—it's about optimizing the way you age.
Why Wonderfeel Rises Above the Competition
In a supplement space flooded with generic NMN formulas and unproven marketing claims, Wonderfeel differentiates itself through: Doctor-formulated products rooted in biomedical research
Transparent labeling and open access to lab test results
Optimized ingredient synergy for better bioavailability and real-world impact
User-centric design, with flexible subscription models and excellent customer support
Wonderfeel doesn't just sell NMN—it delivers a holistic experience for individuals ready to reclaim control over how they feel, function, and perform as they age.
If your goal is to future-proof your physical and mental well-being through targeted, research-supported interventions, Wonderfeel should be at the top of your list.
Final Thoughts and Important Reminders
Before starting any new supplement, it's wise to consult with your healthcare provider, especially if you're managing underlying conditions or taking medication. Wonderfeel's products are generally well-tolerated, but results can vary by age, health status, and consistency of use.
Disclaimer: These supplements are not intended to diagnose, treat, cure, or prevent any disease. Statements are based on emerging science and user reports, not FDA evaluations.
If you're ready to experience what high-purity NMN and targeted antioxidant support can do for your body and mind, Wonderfeel offers one of the most complete and trusted options in today's rapidly growing field of cellular longevity support.
Where to Buy and Stay Updated
Wonderfeel NMN supplements are available exclusively through the official Wonderfeel website:
https://getwonderfeel.com
Pricing Disclaimer: Prices are subject to change. Always check the official website for the most accurate and updated information before purchasing.
By ordering directly, you gain access to: Subscription discounts
Exclusive bundles and limited-time offers
Access to upcoming product innovations
Frequently Asked Questions (FAQs)
1. What is Wonderfeel NMN and how does it support NAD+ levels?
Wonderfeel NMN supplements—specifically Youngr™ and Capsuls™—are advanced formulations designed to increase NAD+ production in the body. NAD+ is essential for cellular energy, DNA repair, and healthy aging. By supplementing with Nicotinamide Mononucleotide (NMN), Wonderfeel helps replenish declining NAD+ levels, promoting mitochondrial health and cellular rejuvenation.
2. How is Wonderfeel Youngr™ different from other NMN supplements?
Wonderfeel Youngr™ is distinct in its formulation, combining 900 mg of NMN with potent antioxidants like resveratrol, hydroxytyrosol, ergothioneine, and vitamin D3. This unique blend supports sirtuin activation, reduces oxidative stress, and provides neuroprotective benefits, making it a comprehensive longevity supplementunlike single-compound NMN products.
3. Who should consider taking Wonderfeel NMN supplements?
Wonderfeel NMN is ideal for adults seeking anti-aging support, energy enhancement, and cognitive clarity. It's especially beneficial for individuals over 35 experiencing fatigue, focus issues, or slowed recovery, and for biohackers or health-conscious consumers looking to boost cellular energy and overall vitality through NAD+ optimization.
4. Is NMN better than NR for boosting NAD+?
While both NMN and NR are NAD+ precursors, NMN is often considered more effective due to its direct conversion into NAD+ in tissues like the brain and muscles. Wonderfeel uses high-bioavailability NMN in both Youngr™ and Capsuls™, providing targeted support for metabolic health and cellular longevity.
5. Are Wonderfeel NMN supplements safe to use daily?
Yes, Wonderfeel's NMN supplements are not just safe, but they are also manufactured in cGMP-certified U.S. facilities, third-party tested for quality, and made with clean, non-GMO, vegan ingredients. This ensures that you're getting a high-quality product that you can trust. While NMN is generally well-tolerated, we always recommend consulting your healthcare provider before starting any new supplement.
Disclaimer: These supplements are not intended to diagnose, treat, cure, or prevent any disease.
6. What results can I expect from taking Wonderfeel Youngr™ or Capsuls™?
Most users report increased energy, mental clarity, improved focus, and enhanced stress resilience within weeks. Some also notice better sleep and skin quality. Results vary depending on health status and consistency.
Disclaimer: We understand that individual experiences may vary. While most users report increased energy, mental clarity, improved focus, and enhanced stress resilience within weeks, some may notice other benefits like better sleep and skin quality. However, these supplements are not a replacement for professional medical treatment.
7. Can I take Wonderfeel Capsuls™ with other supplements?
Yes. Wonderfeel Capsuls™ contains 1000 mg of pure NMN with no additional ingredients, making it ideal for stacking with other supplements like resveratrol, CoQ10, or multivitamins. It's designed for people seeking a customizable NAD+ support routine.
8. How long does it take to feel the effects of NMN?
While some people report noticeable effects within a few days, most experience benefits after 2–4 weeks of consistent use. NAD+ levels build gradually, and benefits compound over time with long-term supplementation.
9. Is there a difference between the subscription and one-time purchase?
Yes, there is a difference. With a monthly subscription, you save on each bottle—$73 for Youngr™ (vs $88) and $52 for Capsuls™ (vs $58). Subscriptions offer convenience and better value, especially for long-term NAD+ support.
Disclaimer: Always check the official website for the latest prices, as pricing is subject to change.
10. Where can I buy Wonderfeel NMN supplements?
Wonderfeel NMN products are available exclusively through the official website: https://getwonderfeel.com. Buying direct ensures access to genuine formulas, subscription savings, lab-tested quality, and customer support.
A longer life means nothing without quality—give your cells the fuel they need to thrive with Wonderfeel's NMN supplements. Start feeling younger now. Company: Wonderfeel NMN
Email: [email protected]
Order Phone Support: +1-415-376-6516
Disclaimers and Disclosures
The information provided in this article is for general informational and educational purposes only and should not be construed as medical advice, diagnosis, or treatment. The content is based on publicly available sources and the manufacturer's official product descriptions at the time of writing. While efforts have been made to ensure the accuracy and completeness of the information presented, no guarantees are made regarding its reliability or applicability to individual circumstances.
Your well-being is our top priority. We strongly advise you to consult a qualified healthcare professional before starting any new dietary supplement, especially if you have underlying health conditions, are pregnant or nursing, or are currently taking prescription medications. Remember, any product mentioned in this article is not intended to diagnose, treat, cure, or prevent any disease, and has not been evaluated by the Food and Drug Administration (FDA).
It's important to note that individual results may vary. The testimonials and anecdotal experiences quoted throughout the article are for illustrative purposes only and may not reflect typical results. We understand that each person's body is unique and may respond differently to dietary supplements.
The publisher, contributors, and any associated distribution or syndication channels shall not be held liable for any direct or indirect damages, loss, or injury caused or alleged to be caused by the use or reliance upon any product, idea, or recommendation mentioned herein. This includes but is not limited to typographical errors, outdated pricing, or incorrect ingredient specifications that may have changed after publication.
All pricing, shipping terms, and refund policies referenced in this article are subject to change at the discretion of the manufacturer. For the most current and accurate product information, readers should visit the official Wonderfeel website at https://getwonderfeel.com.
This article may contain affiliate links, which means a commission may be earned if a reader chooses to purchase a product through one of these links. These links are included to help support the continued creation of useful, independent content, and they come at no additional cost to the consumer. It's important to note that the inclusion of affiliate links does not influence editorial integrity or the objectivity of any product recommendations made.
All trademarks, logos, and brand names mentioned are the property of their respective owners. Their use in this article is for educational and descriptive purposes only, and it does not imply endorsement unless explicitly stated. Any comparisons or references to other supplement brands are included for educational context only.
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Wire
42 minutes ago
- Business Wire
Samsung Bioepis Presents Long-Term Safety Data of EPYSQLI™ (Eculizumab) in PNH at the European Hematology Association (EHA) Congress 2025
INCHEON, Korea--(BUSINESS WIRE)--Samsung Bioepis Co., Ltd. ('Samsung Bioepis') today presented the long-term safety data of EPYSQLI™ (eculizumab; SB12), a biosimilar to Soliris 1, in paroxysmal nocturnal hemoglobinuria (PNH) at the European Hematology Association (EHA) Congress 2025 held at Milan, Italy from June 12 to 15. Long-term follow-up of EPYSQLI's Phase 3 study showed consistency of safety data between the initial 52-week period and the extended treatment period up to 158 weeks Share EPYSQLI was approved by the European Commission (EC) for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) in May 2023 and March 2024, respectively 2. The study assessed the long-term safety of EPYSQLI in PNH patients by evaluating the consistency of safety outcomes, particularly serious adverse events (SAEs) between the initial 52-week Phase 3 study period and the extended treatment (ET) period, spanning from 52 weeks to up to 158 weeks. The same maintenance dose of 900 mg EPYSQLI was administered every 2 weeks. A total of 46 patients from the Phase 3 study received ET. During ET, seven patients (15.2%) experienced a total of 14 SAEs with no occurrence of fatal cases, and all patients fully recovered without permanently discontinuing the treatment. The exposure-adjusted event rate (EAER) was comparable between initial 52-week period and ET period (EAER were 0.13 and 0.17, respectively), and there was no statistically difference between initial 52-week and ET period in EAER (p-value = 0.76). The study is consistent with the findings of the Phase 3 study with no newly identified safety signals and no fatal cases occurred throughout the entire treatment period with all SAEs resolving completely. Details of the abstract are as follows 3: Abstract title: Long-Term Safety of SB12 in Paroxysmal Nocturnal Hemoglobinuria: Up to 2-year Extension Treatment Safety Data Abstract number: PB2811 Type: Publication Only Session title: Bone marrow failure syndromes incl. PNH – Clinical Author(s): Jun Ho Jang, Siook Baek, Yumin Baek, Jinah Jung, Ciprian Tomuleasa, Hanna Oliynyk, Theerin Lanamtieng, Soo Min Lim Besides approval by the EC, EPYSQLI is also approved by the U.S. Food and Drug Administration (FDA) and Korea's Ministry of Food and Drug Safety (MFDS) as a biosimilar to Soliris. In countries where EPYSQLI is approved and available, EPYSQLI may not be prescribed and/or dispensed for its unapproved other indications for which Soliris is approved. About EPYSQLI (Eculizumab Biosimilar) in the European Union (EU) EPYSQLI is indicated in adults and children for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). EPYSQLI is not approved for and should not be used for the treatment of generalised myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). EPYSQLI must be administered by a healthcare professional and under the supervision of a physician experienced in the management of patients with hematological disorders or renal disorders. EPYSQLI EU Important Safety Information The EU Summary of Product Characteristics for EPYSQLI includes the following Special warning and Precautions: Meningococcal Infection Due to its mechanism of action, the use of eculizumab increases the patient's susceptibility to meningococcal infection (Neisseria meningitidis). Meningococcal disease due to any serogroup may occur. To reduce the risk of infection, all patients must be vaccinated at least 2 weeks prior to receiving eculizumab unless the risk of delaying eculizumab therapy outweighs the risks of developing a meningococcal infection. Patients who initiate eculizumab treatment less than 2 weeks after receiving a tetravalent meningococcal vaccine must receive treatment with appropriate prophylactic antibiotics until 2 weeks after vaccination. Vaccines against serogroups A, C, Y, W 135 are recommended in preventing the commonly pathogenic meningococcal serogroups. Vaccine against serogroup B where available is also recommended. Patients must receive vaccination according to current national vaccination guidelines for vaccination use. Vaccination may further activate complement. As a result, patients with complement-mediated diseases, including PNH and aHUS, may experience increased signs and symptoms of their underlying disease, such as haemolysis (PNH) or TMA (aHUS). Therefore, patients should be closely monitored for disease symptoms after recommended vaccination. Vaccination may not be sufficient to prevent meningococcal infection. Consideration should be given to official guidance on the appropriate use of antibacterial agents. Cases of serious or fatal meningococcal infections have been reported in eculizumab-treated patients. Sepsis is a common presentation of meningococcal infections in patients treated with eculizumab. All patients should be monitored for early signs of meningococcal infection, evaluated immediately if infection is suspected, and treated with appropriate antibiotics if necessary. Patients should be informed of these signs and symptoms and steps taken to seek medical care immediately. Other Systemic Infections Patients may have increased susceptibility to other type of serious infections, especially with Neisseria and encapsulated bacteria. Infusion Reactions Administration of eculizumab may result in infusion reactions or immunogenicity that could cause allergic or hypersensitivity reactions (including anaphylaxis). Eculizumab administration should be interrupted in all patients experiencing severe infusion reactions and appropriate medical therapy administered. Anticoagulant therapy Treatment with eculizumab should not alter anticoagulant management. PNH Laboratory Monitoring PNH patients should be monitored for signs and symptoms of intravascular haemolysis, including serum lactate dehydrogenase (LDH) levels, and may require dose adjustment within the recommended 14±2 day dosing schedule during the maintenance phase (up to every 12 days). aHUS Laboratory Monitoring aHUS patients receiving eculizumab therapy should be monitored for thrombotic microangiopathy by measuring platelet counts, serum LDH and serum creatinine, and may require dose adjustment within the recommended 14±2 day dosing schedule during the maintenance phase (up to every 12 days). Treatment Discontinuation for PNH If patients discontinue treatment with eculizumab they should be closely monitored for signs and symptoms of serious intravascular haemolysis. Treatment Discontinuation for aHUS If aHUS patients discontinue treatment with eculizumab, they should be monitored closely for signs and symptoms of severe thrombotic microangiopathy complications. The most common adverse reaction observed with eculizumab treatment in clinical trials was headache, (occurred mostly in the initial phase of dosing), and the most serious adverse reaction was found to be meningococcal infection. Refer to the Summary of Product Characteristics for EPYSQLI's full safety information.
Yahoo
2 hours ago
- Yahoo
Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity
Dapirolizumab pegol (DZP) showed efficacy across multiple clinical endpoints in the PHOENYCS GO study, including fatigue and measures of disease activity DZP showed consistent improvements in fatigue, a common and debilitating symptom of systemic lupus erythematosus (SLE) At Week 48, more individuals receiving DZP experienced no or low disease activity compared to standard of care with differences observed as early as Week 12 BRUSSELS and CAMBRIDGE, Mass., June 12, 2025 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Biogen Inc. (NASDAQ: BIIB) today presented additional detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol (DZP), a novel Fc-free anti-CD40L drug candidate. In the study, DZP demonstrated significant clinical improvements in disease activity in people living with moderate-to-severe systemic lupus erythematosus (SLE), as measured by the British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) at Week 48, the primary endpoint. Improvements were also seen across additional clinical measures, including fatigue and disease activity/remission. These results were presented at EULAR 2025, the European Alliance of Associations for Rheumatology's annual meeting, in Barcelona, Spain. The safety and efficacy of DZP in SLE have not been established, and it is not approved for use in SLE by any regulatory authority worldwide. A second Phase 3 trial of dapirolizumab pegol is ongoing with the goal of confirming the results from PHOENYCS GO. 'Despite being a common manifestation of systemic lupus erythematosus, fatigue is a difficult-to-treat symptom that can severely impact a person's quality of life, and remains a challenge to address,' said Ioannis Parodis, MD, PhD, Associate Professor of Rheumatology, Karolinska University Hospital, Sweden. 'The results we observed in this Phase 3 study indicate that participants treated with dapirolizumab pegol have the potential to achieve consistent improvements in fatigue beyond the current standard of care.' In an analysis of the impact of DZP on patient-reported fatigue in people with SLE participating in the PHOENYCS GO study, individuals receiving DZP in addition to standard of care (SOC) treatment demonstrated improvements across two fatigue measurements: Improvements in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue scores were greater in the DZP group (change from baseline, 8.9), compared with SOC alone (5.2; nominal* p=0.0024) at Week 48. Using FATIGUE-PRO, a measure recently developed to capture the patient experience of fatigue in SLE, greater improvements from baseline (nominal* p<0.05) were observed in people receiving DZP compared with SOC alone in the Physical Fatigue (change from baseline difference between groups,7.6), Mental and Cognitive (5.6), and Susceptibility to Fatigue (7.8) scales at Week 48. 'Being able to address both fatigue and remission are areas of critical unmet need in lupus care, an important treatment goal is to improve the quality of life for patients as well as to reduce the long-term risk of organ damage through disease remission,' said Eric F. Morand, MBBS, Head of the Monash Health Rheumatology Unit, Monash University, Australia. 'In the PHOENYCS GO study, dapirolizumab pegol has shown meaningful impact in helping patients achieve remission and low disease activity, offering the exciting possibility for improved disease control while reducing exposure to glucocorticoids. Dapirolizumab pegol has the potential to become a significant new medication for people living with SLE, as shown by the breadth of effect seen in the study and I look forward to seeing results from the second Phase 3 study.' In an additional analysis, improvements were seen on measures of low disease activity, as measured by Low Lupus Disease Activity State (LLDAS) and disease remission, as measured by Definition of Remission in SLE (DORIS). Both measures include assessments of disease activity, in addition to a required low dose glucocorticoid intake (<7.5 mg prednisone / day in LLDAS; <5 mg prednisone / day in DORIS). At Week 48, the percentage of participants achieving low disease activity in the DZP group was twice that of the SOC only group (40.9% and 19.6%, respectively; nominal* p<0.0001). As early as Week 12, greater proportions of participants receiving DZP plus SOC achieved LLDAS versus SOC alone (nominal* p<0.05). 23.6% of participants receiving DZP plus SOC achieved low disease activity in ≥50% of visits through 48 weeks compared with 15.9% receiving SOC alone (nominal* p=0.1042). A higher proportion of those receiving DZP (19.2%) versus SOC alone (8.4%) also achieved DORIS at Week 48 (nominal* p=0.0056). * Having met the primary endpoint, improvement of moderate-to-severe disease activity as assessed by achievement of BICLA after 48 weeks and the key secondary endpoint having a p-value = 0.1776, all subsequent secondary and tertiary endpoints are descriptive and nominal p-values are included. The safety profile of DZP was generally favorable. The safety results were consistent with previous DZP studies and with that in study participants with SLE receiving an immunomodulator. A higher proportion of individuals receiving DZP plus SOC had treatment-emergent adverse events (TEAEs) compared to SOC alone (82.6% vs. 75.0%). The proportion of participants with serious TEAEs was 9.9% in participants receiving DZP plus SOC was lower as compared to 14.8% in those receiving SOC alone. Discontinuation of treatment or study participation due to TEAEs occurred in 4.7% (10) of participants receiving DZP plus SOC and 3.7% (4) of participants receiving SOC alone. Participants from the PHOENYCS GO study (NCT04294667) will continue to be followed in a long-term open-label study. A second Phase 3 trial of dapirolizumab pegol, PHOENYCS FLY (NCT06617325) is ongoing. About Systemic Lupus Erythematosus (SLE)SLE is a chronic, multifactorial autoimmune disease that is caused by the activation of autoreactive T, B and antigen-presenting cells, resulting in manifestations across multiple organ systems with periods of illness or flares alternating with periods of inactivity.1 SLE can present itself in several ways including rash, arthritis, anemia, thrombocytopenia, serositis, nephritis, seizures or psychosis.2 SLE is associated with a greater risk of death from causes such as infection and cardiovascular disease. An estimated 90% of people living with lupus are women; most begin to see symptoms between the ages of 15-55.3,4,5 Individuals from populations of African, Hispanic, Asian and Native American descent are at a greater risk of earlier onset and more aggressive disease.6,7 Pregnancy in women with SLE is high risk, with higher maternal and fetal mortality and morbidity than the general population.8,9 About Dapirolizumab PegolDapirolizumab pegol is a novel investigational humanized Fc-free polyethylene glycol (PEG)-conjugated antigen-binding (Fab') fragment. Dapirolizumab pegol inhibits CD40L signaling which has been shown to reduce B cell activation and autoantibody production, mitigate type 1 interferon (IFN) secretion, and attenuate T cell and antigen-presenting cell (APC) activation.10 Dapirolizumab pegol is presently in Phase 3 clinical development for the treatment of systemic lupus erythematosus (SLE) under a collaboration between UCB and Biogen.11 About UCBUCB, Brussels, Belgium ( is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 9,000 people in approximately 40 countries, the company generated revenue of €6.1 billion in 2024. UCB is listed on Euronext Brussels (symbol: UCB). About BiogenFounded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patient's lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth. The company routinely posts information that may be important to investors on its website at Follow us on social media - Facebook, LinkedIn, X, YouTube. Forward looking statements UCBThis document contains forward-looking statements, including, without limitation, statements containing the words 'potential', 'believes', 'anticipates', 'expects', 'intends', 'plans', 'seeks', 'estimates', 'may', 'will', 'continue' and similar expressions. These forward-looking statements are based on current plans, estimates and beliefs of management. All statements, other than statements of historical facts, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, arbitration, political, regulatory or clinical results or practices and other such estimates and results. By their nature, such forward-looking statements are not guaranteeing future performance and are subject to known and unknown risks, uncertainties, and assumptions which might cause the actual results, financial condition, performance or achievements of UCB, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements contained in this document. Important factors that could result in such differences include but are not limited to: global spread and impacts of wars, pandemics and terrorism, the general geopolitical environment, climate change, changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms or within expected timing, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, safety, quality, data integrity or manufacturing issues, supply chain disruption and business continuity risks; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, product liability claims, challenges to patent protection for products or product candidates, competition from other products including biosimilars or disruptive technologies/business models, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws, and hiring, retention and compliance of its employees. There is no guarantee that new product candidates will be discovered or identified in the pipeline, or that new indications for existing products will be developed and approved. Movement from concept to commercial product is uncertain; preclinical results do not guarantee safety and efficacy of product candidates in humans. So far, the complexity of the human body cannot be reproduced in computer models, cell culture systems or animal models. The length of the timing to complete clinical trials and to get regulatory approval for product marketing has varied in the past and UCB expects similar unpredictability going forward. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to disputes between the partners or may prove to be not as safe, effective or commercially successful as UCB may have believed at the start of such partnership. UCB's efforts to acquire other products or companies and to integrate the operations of such acquired companies may not be as successful as UCB may have believed at the moment of acquisition. Also, UCB or others could discover safety, side effects or manufacturing problems with its products and/or devices after they are marketed. The discovery of significant problems with a product similar to one of UCB's products that implicate an entire class of products may have a material adverse effect on sales of the entire class of affected products. Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment, including pricing pressure, political and public scrutiny, customer and prescriber patterns or practices, and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement activities and outcomes. Finally, a breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of UCB's data and systems. Given these uncertainties, the public is cautioned not to place any undue reliance on such forward-looking statements. These forward-looking statements are made only as of the date of this document, and do not reflect any potential impacts from the evolving event or risk as mentioned above as well as any other adversity, unless indicated otherwise. The company continues to follow the development diligently to assess the financial significance of these events, as the case may be, to UCB. UCB expressly disclaims any obligation to update any forward-looking statements in this document, either to confirm the actual results or to report or reflect any change in its forward-looking statements with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless such statement is required pursuant to applicable laws and regulations. Biogen Safe Harbor This press release contains forward-looking statements, relating to: our strategy and plans; potential of, and expectations for, our commercial business and pipeline programs; capital allocation and investment strategy; clinical development programs, clinical trials, and data readouts and presentations; regulatory discussions, submissions, filings, and approvals; the potential benefits, safety, and efficacy of our and our collaboration partners' products and investigational therapies; the anticipated benefits and potential of investments, actions to improve risk profile and productivity of R&D pipeline, collaborations, and business development activities; and our future financial and operating results. These forward-looking statements may be accompanied by such words as 'aim,' 'anticipate,' 'assume,' 'believe,' 'contemplate,' 'continue,' 'could,' 'estimate,' 'expect,' 'forecast,' 'goal,' 'guidance,' 'hope,' 'intend,' 'may,' 'objective,' 'outlook,' 'plan,' 'possible,' 'potential,' 'predict,' 'project,' 'prospect,' 'should,' 'target,' 'will,' 'would,' and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements. Given their forward-looking nature, these statements involve substantial risks and uncertainties that may be based on inaccurate assumptions and could cause actual results to differ materially from those reflected in such statements. This press release includes, among others, forward-looking statements including: that Biogen is building on a new foundation with the goal of long-term sustainable growth in its commercial portfolio; the multi-billion dollar potential of its late-stage pipeline; that we believe there remains a significant long-term opportunity for our ongoing product launches including LEQEMBI; that we believe that continued execution against these key strategic elements, as well as a disciplined approach to business development, will allow us to generate long-term value for our shareholders by bringing innovative medicines to patients; and all statements and information under the heading "Full Year 2025 Financial Guidance". These forward-looking statements are based on management's current beliefs and assumptions and on information currently available to management. Given their nature, we cannot assure that any outcome expressed in these forward looking statements will be realized in whole or in part. We caution that these statements are subject to risks and uncertainties, many of which are outside of our control and could cause future events or results to be materially different from those stated or implied in this document, including, among others, factors relating to: our substantial dependence on revenue from our products and other payments under licensing, collaboration, acquisition or divestiture agreements; uncertainty of long-term success in developing, licensing, or acquiring other product candidates or additional indications for existing products; expectations, plans and prospects relating to product approvals, approvals of additional indications for our existing products, sales, pricing, growth, reimbursement and launch of our marketed and pipeline products; the potential impact of increased product competition in the biopharmaceutical and healthcare industry, as well as any other markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways; our ability to effectively implement our corporate strategy; the successful execution of our strategic and growth initiatives, including acquisitions; the drivers for growing our business; difficulties in obtaining and maintaining adequate coverage, pricing, and reimbursement for our products; the drivers for growing our business, including our dependence on collaborators and other third parties for the development, regulatory approval, and commercialization of products and other aspects of our business, which are outside of our full control; risks associated with current and potential future healthcare reforms; risks related to commercialization of biosimilars, which is subject to such risks related to our reliance on third parties, intellectual property, competitive and market challenges and regulatory compliance; failure to obtain, protect, and enforce our data, intellectual property, and other proprietary rights and the risks and uncertainties relating to intellectual property claims and challenges; the risk that positive results in a clinical trial may not be replicated in subsequent or confirmatory trials or success in early stage clinical trials may not be predictive of results in later stage or large scale clinical trials or trials in other potential indications; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; the occurrence of adverse safety events, restrictions on use with our products, or product liability claims; risks relating to technology, including our incorporation of new technologies such as artificial intelligence into some of our processes; risks related to use of information technology systems and potential impacts of any breakdowns, interruptions, invasions, corruptions, data breaches, destructions and/or other cybersecurity incidents of our systems or those of connected and/or third-party systems; problems with our manufacturing capacity, including our ability to manufacture products efficiently or adequately address global bulk supply risks; risks relating to management, personnel and other organizational changes, including our ability to attracting, retaining and motivating qualified individuals; risks related to the failure to comply with current and new legal and regulatory requirements, including judicial decisions, accounting standards, and tariff or trade restrictions; the risks of doing business internationally, including geopolitical tensions, acts of war and largescale crises; risks relating to investment in our manufacturing capacity; risks relating to the distribution and sale by third parties of counterfeit or unfit versions of our products; risks relating to the use of social media for our business, results of operations and financial condition; fluctuations in our operating results; risks related to investment in properties; risks relating to access to capital and credit markets to finance our present and future operations and business initiatives and obtain funding for such activities on favorable terms; risks related to indebtedness; the market, interest, and credit risks associated with our investment portfolio; risks relating to share repurchase programs; change in control provisions in certain of our collaboration agreements; fluctuations in our effective tax rate and obligations in various jurisdictions in which we are subject to taxation; environmental risks; and any other risks and uncertainties that are described in other reports we have filed with the U.S. Securities and Exchange Commission. These statements speak only as of the date of this press release and are based on information and estimates available to us at this time. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. Investors are cautioned not to put undue reliance on forward-looking statements. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and in our subsequent reports on Form 10-Q and Form 10-K, in each case including in the sections thereof captioned 'Note Regarding Forward-Looking Statements' and 'Item 1A. Risk Factors,' and in our subsequent reports on Form 8-K. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements whether as a result of any new information, future events, changed circumstances or otherwise. References: Tselios K, Gladman DD, Touma Z, et al. Disease course patterns in systemic lupus erythematosus. Lupus. 2019;28(1):114-122. Fanouriakis A, Tziolos N, Bertsias G, et al. Update οn the diagnosis and management of systemic lupus erythematosus. Ann Rheum Dis. 2021;80(1):14-25. doi:10.1136/annrheumdis-2020-218272 Petri M. Epidemiology of systemic lupus erythematosus. Best Pract Res Clin Rheumatol. 2002;16(5):847-58. Epub 2002/12/11. doi: 10.1053/berh.2002.0259. PubMed PMID: 12473278. Rees F, Doherty M, Grainge M, Davenport G, Lanyon P, Zhang W. The incidence and prevalence of systemic lupus erythematosus in the UK, 1999-2012. Ann Rheum Dis. 2016;75(1):136-41. Epub 2014/10/01. doi: 10.1136/annrheumdis-2014-206334. PubMed PMID: 25265938; PubMed Central PMCID: PMCPMC4717400. Pons-Estel GJ, Ugarte-Gil MF, Alarcón GS. Epidemiology of systemic lupus erythematosus. Expert Rev Clin Immunol. 2017;13(8):799-814. Carter EE, Barr SG, Clarke AE. The global burden of SLE: prevalence, health disparities and socioeconomic impact. Nat Rev Rheumatol. 2016;12(10):605-20. Epub 2016/08/26. doi: 10.1038/nrrheum.2016.137. PubMed PMID: 27558659. Kheir JM, Guthridge CJ, Johnston JR, Adams LJ, Rasmussen A, Gross TF, et al. Unique clinical characteristics, autoantibodies and medication use in Native American patients with systemic lupus erythematosus. Lupus Sci Med. 2018;5(1):e000247. Epub 2018/03/14. doi: 10.1136/lupus-2017-000247. PubMed PMID: 29531773; PubMed Central PMCID: PMCPMC5844376. Mehta B, Luo Y, Xu J, Sammaritano L, Salmon J, Lockshin M, et al. Trends in Maternal and Fetal Outcomes Among Pregnant Women With Systemic Lupus Erythematosus in the United States: A Cross-sectional Analysis. Ann Intern Med. 2019;171(3):164-71. Epub 2019/07/10. doi: 10.7326/M19-0120. PubMed PMID: 31284305. Bitencourt N, Bermas BL. Pharmacological Approach to Managing Childhood-Onset Systemic Lupus Erythematosus During Conception, Pregnancy and Breastfeeding. Paediatr Drugs. Furie RA, Bruce IN, Dörner T, et al. Phase 2 randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate to severe active systemic lupus erythematosus (SLE). Rheumatology (Oxford).2021;60(11): 5397-407. (NCT04294667). A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus (PHOENYCS GO) 2023 [cited August 2024] Available at: Retrieved July 25, 2024. MEDIA CONTACTS:UCBAdriaan Snauwaert+32 497 70 23 BiogenJack Cox+1 781 464 INVESTOR CONTACTS:UCBAntje Witte+32 2 559 Power+ 1 781 464 2442IR@
Yahoo
3 hours ago
- Yahoo
Global Fatty Liver Day 2025: Elevating Liver Health in the Metabolic Health Conversation
Global Liver Institute Calls for Urgent Action as Fatty Liver Disease Prevalence Surges Worldwide Today is Global Fatty Liver Day Washington, D.C., June 11, 2025 (GLOBE NEWSWIRE) -- On the second Thursday in June, Global Fatty Liver Day (formerly International NASH Day) spotlights one of the most widespread yet under-addressed health threats of our time: fatty liver disease, increasingly referred to as steatotic liver disease (SLD) in clinical settings. Hosted annually by Global Liver Institute (GLI), this public awareness campaign raises awareness of this silent epidemic and its deep roots in global metabolic health liver disease, including metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction-associated steatohepatitis (MASH) and metabolic dysfunction-associated alcohol-related liver disease (MetALD), impacts millions globally—yet most remain undiagnosed and untreated. Once considered rare, fatty liver disease has surged in parallel with rising rates of obesity, diabetes, and other metabolic estimated 30.2% of the global population now lives with MASLD, with rates soaring to 57.5% among adults with obesity. In the United States alone, more than 122 million adults are projected to be affected by R. Holden, President and CEO of Global Liver Institute, states, 'The liver is no longer the silent organ. Fatty liver disease is now one of the clearest and most urgent signs of global metabolic dysfunction. On Global Fatty Liver Day, we call on healthcare leaders, policymakers, and the public to recognize the liver's central role in preventing not just liver disease—but cardiovascular disease, diabetes, and other non-communicable diseases (NCDs). Liver health must rise to the top of public health agendas globally.'Fatty liver disease develops when excess fat accumulates in the liver, often without symptoms in its early stages. Left unaddressed, it can progress to inflammation, fibrosis, cirrhosis, liver cancer, and even death. In fact, MASH is now one of the leading causes of liver transplantation in the fatty liver disease doesn't occur in isolation: Up to 75% of people with type 2 diabetes also have MASLD Over 70% of people with MASLD also live with obesity Between 20% and 80% of individuals with high cholesterol or triglycerides are also affected by fatty liver disease 'Fatty liver disease is not just about the liver—it's about the entire metabolic ecosystem,' said Sharon Jaycox, PhD, Fatty Liver Disease Program Director at GLI. 'If we fail to address it, we miss a major opportunity to detect and treat metabolic dysfunction early. We must educate patients and providers alike, embed liver screening in diabetes and obesity care, and drive equitable access to diagnostics and care.' GLI urges coordinated action across health systems, communities, and governments to: Incorporate liver screening into routine care for those with obesity, diabetes, and other metabolic risks Educate the public and clinicians about MASLD, MASH, and MetALD as part of integrated metabolic care Expand access to affordable, noninvasive diagnostic tools Support policies and funding that reflect the scale and urgency of the fatty liver disease crisis As GLI continues to lead this global awareness effort, we invite stakeholders to join us in bringing liver health into every metabolic health to learn more, access resources, and take action on Global Fatty Liver Day. Attachment Today is Global Fatty Liver Day CONTACT: Christine Maalouf Global Liver Institute cmaalouf@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data